Effect of dilazep dihydrochloride on urinary albumin excretion in patientswith autosomal dominant polycystic kidney disease

Proteinuria and microalbuminuria occur with a highly variable severity and are associated with progression of autosomal dominant polycystic kidney dis ease (ADPKD), Dilazep dihydrochloride, an antiplatelet drug, is effective i n patients with immunoglobulin A nephropathy or diabetic nephropathy. We st udied whether dilazep dihydrochloride affects the urinary albumin excretion (UAE) in normotensive and hypertensive patients with ADPKD. Twelve normote nsive ADPKD patients with microalbuminuria were randomly assigned to two gr oups: a dilazep (300 mg/day) treatment group (n = 6, group A) and a placebo group (n = 6, group B). In addition, 10 hypertensive ADPKD patients with m icroalbuminuria were randomly assigned to two groups: a dilazep (300 mg/day ) treatment group (n = 5, group C) and a placebo group (n = 5, group D). Tr eatment with dilazep was continued for a period of 6 months, at the end of which the UAE was reduced form 130 +/- 52 to 46 +/- 26 mug/min (p < 0.01) i n group A. There was no reduction in group C. There were no changes in UAE in placebo groups B and D. These results suggest that dilazep dihydrochlori de may be effective in reducing UAE in normotensive ADPKD patients with mic roalbuminuria. Copyright (C) 2001 S. Karger AG, Basel.